Cardiocast

Analysis shows ‘Devil’s bargain’ in cardiac arrest


 

The “Devil’s bargain” of epinephrine use in cardiac arrest plays out in a new analysis. Also this week, updated recommendations reflect maturation of transcatheter aortic valve replacement, a comparison of cardiovascular protection in type 2 diabetes drugs, and sweeping reductions in documentation requirements headline a new Medicare fee schedule proposal. Listen on iTunes.

Recommended Reading

Alirocumab’s benefit greater in diabetes patients: ODYSSEY Outcomes
MDedge Cardiology
New look at ATLAS suggests rivaroxaban may still have role in ACS
MDedge Cardiology
DOJ lawsuit reins in inappropriate ICD use
MDedge Cardiology
Alteplase, aspirin provide similar functional outcomes after nondisabling stroke
MDedge Cardiology
Obesity triples post-MI sudden cardiac death risk
MDedge Cardiology
Older black patients die sooner after in-hospital cardiac arrest
MDedge Cardiology
Medicare’s bundled pay plan didn’t deliver big cost savings
MDedge Cardiology
Epinephrine for cardiac arrest: Better survival, more brain damage
MDedge Cardiology
Culotte stenting impresses in CELTIC Bifurcation Study
MDedge Cardiology
No benefit of direct stenting in PCI
MDedge Cardiology